ExelixisÖÆÒ©¹«Ë¾½üÈÕÐû²¼ÓëĬ¿Ë£¨Merck KGaA£©ºÍ»ÔÈð£¨Pfizer£©´ï³ÉÒ»ÏîÁÙ´²ÊÔÑéºÏ×÷ºÍ¹©Ó¦ÐÒ飬ÔÚÕýÔÚ½øÐеÄ1bÆÚ¼ÁÁ¿µÝÔöÑо¿STELLAR-001£¨ÒÔǰ³ÆÎª¡°XL092-001¡±£©ÖУ¬Ôö¼Ó3¸öеĶÓÁУ¬ÆÀ¹ÀXL092ÁªºÏ¿¹PD-L1ÃâÒß¼ì²éµãÒÖÖÆ¼Á£¨ICI£©Bavencio£¨avelumab£©ÖÎÁƾֲ¿ÍíÆÚ»ò×ªÒÆÐÔÄò·ÉÏÆ¤°©£¨UC£¬×î³£¼ûµÄ°òë×°©ÀàÐÍ£©»¼ÕߵݲȫÐÔºÍÄÍÊÜÐÔ¡£
LATEST POSTS
×îÐÂ×ÊѶ
µ±ÎÒÃÇÏëµ½ÓÕ·¢Éñ¾ÏµÍ³¼²²¡µÄÔÒòÒÔ¼°ÈçºÎÖÎÁÆÊ±£¬ÎÒÃÇͨ³£»áÏëµ½Õë¶Ô´óÄÔÀ´½øÐÐÑо¿£»µ«Õâµ½µ×ÊDz»ÊÇ×î¼ÑµÄ·½·¨»òÕßΨһµÄ·½ÏòÄØ£¿ÈÕǰ£¬Ò»Æª·¢±íÔÚ¹ú¼ÊÔÓÖ¾CellÉÏÌâΪ¡°Dissecting the contribution of host genetics and the microbiome in complex behaviors¡±µÄÑо¿±¨¸æÖУ¬À´×ÔÃÀ¹ú±´ÀÕҽѧԺµÈ»ú¹¹µÄ¿ÆÑ§¼ÒÃÇͨ¹ýÑо¿·¢ÏÖ£¬³¦µÀÖеÄ΢ÉúÎï»òÐí»áÓÕ·¢Ó븴ÔÓÉñ¾ÏµÍ³¼²²¡Ïà¹ØµÄijЩ¼²²¡Ö¢×´£¬Òò´Ë»ùÓÚ΢ÉúÎïµÄÁÆ·¨Î´À´»òÓÐÍû°ïÖúÖÎÁÆÈËÀàµÄÉñ¾ÏµÍ³¼²²¡¡£
LATEST POSTS